EN PL

EMEA: Updated EMEA Pre-Submission Procedural Advice

25.08.2009
Updated EMEA Pre-Submission Procedural Advice -Q53 - What do I have to consider regarding the MA of my centrally authorised medicinal product in Norway, Iceland and Liechtenstein?